FGFR2
6 drugs OncologyRespiratory
5
approved indications
6
Approved Drugs
6
Companies
18
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (18 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EISAI INC 1 drug
Eli Lilly 1 drug
Bayer 1 drug
By Therapeutic Area
Other 3 drugs
Oncology 2 drugs
By Therapeutic Area
Other 3 drugs
LENVIMA, STIVARGA, PEMAZYRE
Oncology 2 drugs
RETEVMO, BALVERSA
Respiratory 1 drugs
OFEV
Indications Treated
Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancerAdvanced renal cell carcinoma (first-line, in combination with pembrolizumab)Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus)Unresectable hepatocellular carcinoma (first-line)Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)CholangiocarcinomaMyeloid/Lymphoid NeoplasmsNon-Small Cell Lung CancerMedullary Thyroid CancerThyroid CancerSolid TumorsUrothelial CarcinomaMetastatic colorectal cancerLocally advanced, unresectable or metastatic gastrointestinal stromal tumorHepatocellular carcinomaIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseSystemic Sclerosis-Associated Interstitial Lung Disease